相关实验视频
Updated: Jun 6, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.2K
在卢旺达1型糖尿病患者中持续进行葡萄糖监测 (CAPT1D) 第一阶段:可行性研究
Jason Baker1, Giacomo Cappon2, Jean Claude Habineza3
1Diabetes Empowerment International, 229 E 85th St, New York, US.
JMIR formative research
|November 26, 2024
概括
持续血糖监测 (CGM) 显著改善了卢旺达1型糖尿病患者的血糖控制和时间范围. 这项研究强调了CGM在这个人群中的可行性和影响,显示HbA1c降低,没有严重的低血糖症.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病 技术 技术
- 临床研究 临床研究
背景情况:
- 持续血糖监测 (CGM) 系统彻底改变了糖尿病管理,改善了血糖控制和减少并发症.
- 在卢旺达采用CGM是有限的,没有先前的临床研究在文献中确定.
- 这项研究解决了了解CGM对卢旺达1型糖尿病 (T1D) 影响的差距.
研究的目的:
- 评估卢旺达T1D患者实时CGM使用的影响和可行性.
- 评估传感器粘附度,范围内的时间 (TIR),低血糖/高血糖率,HbA1c水平以及与糖尿病相关的住院治疗.
- 为以前未经研究的人群提供CGM有效性的初步数据.
主要方法:
- 卢旺达1型糖尿病患者持续血糖监测研究 (CAPT1D) 招募了50名患有T1D的成年人,每天接受多次胰岛素注射.
- 使用Dexcom G6 CGM (第一阶段) 进行了为期12个月的前性观察研究.
- 参与者年龄超过21岁,没有怀孕,并且在卢旺达糖尿病协会诊所接受护理.
主要成果:
- 在整个12个月的研究期间观察到高传感器粘附率 (>80%).
- 在3个月内,在范围内的时间得到了显著的改善,并且持续了.
- 6个月后HbA1c水平下降了2.8%,12个月后下降了3.2% (p<0.01),没有报告严重的低血糖或DKA.
结论:
- 实时CGM在卢旺达的T1D患者的血糖指数显著和有意义的改善.
- 这些发现表明,CGM是这种环境中糖尿病管理的可行和有影响力的技术.
- 未来的研究应该探索干预前后分析,以进一步评估关于并发症和成本的有效性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236

